Listed

Nurix Therapeutics, Inc.

NRIXNasdaqCIK 1549595HealthcareFiscal year ends Nov 30

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$673.1m, Q3 FY2026
Operating income$559.5m, Q3 FY2026
Net income$549.8m, Q3 FY2026
Nurix Therapeutics, Inc., income statement, quarterly
Line itemUnitQ4 FY20232023-11-30Q1 FY20242024-02-29Q2 FY20242024-05-31Q3 FY20242024-08-31Q4 FY20242024-11-30Q1 FY20252025-02-28Q2 FY20252025-05-31Q3 FY20252025-08-31Q4 FY20252025-11-30Q1 FY20262026-02-28Q2 FY20262026-05-31Q3 FY20262026-08-31
Revenue$m15.2Revenue, Q4 FY2023, three months to 2023-11-30$15.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure16.6Revenue, Q1 FY2024, three months to 2024-02-29$16.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-04-08, accession 0001549595-25-000055.Report this figure12.1Revenue, Q2 FY2024, three months to 2024-05-31$12.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-07-09, accession 0001549595-25-000095.Report this figure12.6Revenue, Q3 FY2024, three months to 2024-08-31$12.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure13.3Revenue, Q4 FY2024, three months to 2024-11-30$13.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure18.5Revenue, Q1 FY2025, three months to 2025-02-28$18.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure44.1Revenue, Q2 FY2025, three months to 2025-05-31$44.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure7.9Revenue, Q3 FY2025, three months to 2025-08-31$7.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure13.6Revenue, Q4 FY2025, three months to 2025-11-30$13.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure6.3Revenue, Q1 FY2026, three months to 2026-02-28$6.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure9.0Revenue, Q2 FY2026, three months to 2026-05-31$9.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure673Revenue, Q3 FY2026, three months to 2026-08-31$673.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure
Research and development$m49.7Research and development, Q4 FY2023, three months to 2023-11-30$49.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure50.0Research and development, Q1 FY2024, three months to 2024-02-29$50.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-04-08, accession 0001549595-25-000055.Report this figure48.9Research and development, Q2 FY2024, three months to 2024-05-31$48.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-07-09, accession 0001549595-25-000095.Report this figure55.5Research and development, Q3 FY2024, three months to 2024-08-31$55.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure67.2Research and development, Q4 FY2024, three months to 2024-11-30$67.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure69.7Research and development, Q1 FY2025, three months to 2025-02-28$69.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure78.1Research and development, Q2 FY2025, three months to 2025-05-31$78.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure86.1Research and development, Q3 FY2025, three months to 2025-08-31$86.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure83.0Research and development, Q4 FY2025, three months to 2025-11-30$83.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure84.1Research and development, Q1 FY2026, three months to 2026-02-28$84.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure87.7Research and development, Q2 FY2026, three months to 2026-05-31$87.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure79.3Research and development, Q3 FY2026, three months to 2026-08-31$79.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure
Operating income$m(45.3)Operating income, Q4 FY2023, three months to 2023-11-30−$45.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(45.2)Operating income, Q1 FY2024, three months to 2024-02-29−$45.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-04-08, accession 0001549595-25-000055.Report this figure(48.5)Operating income, Q2 FY2024, three months to 2024-05-31−$48.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-07-09, accession 0001549595-25-000095.Report this figure(54.6)Operating income, Q3 FY2024, three months to 2024-08-31−$54.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure(64.7)Operating income, Q4 FY2024, three months to 2024-11-30−$64.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(62.9)Operating income, Q1 FY2025, three months to 2025-02-28−$62.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure(48.3)Operating income, Q2 FY2025, three months to 2025-05-31−$48.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure(91.4)Operating income, Q3 FY2025, three months to 2025-08-31−$91.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure(83.1)Operating income, Q4 FY2025, three months to 2025-11-30−$83.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(92.5)Operating income, Q1 FY2026, three months to 2026-02-28−$92.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure(94.2)Operating income, Q2 FY2026, three months to 2026-05-31−$94.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure559Operating income, Q3 FY2026, three months to 2026-08-31$559.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure
Income tax$m0.0Income tax, Q4 FY2023, three months to 2023-11-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure0.1Income tax, Q1 FY2024, three months to 2024-02-29$90.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-04-08, accession 0001549595-25-000055.Report this figure0.1Income tax, Q2 FY2024, three months to 2024-05-31$90.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-07-09, accession 0001549595-25-000095.Report this figure0.1Income tax, Q3 FY2024, three months to 2024-08-31$82.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-11-30$8.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-02-28$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure0.8Income tax, Q2 FY2025, three months to 2025-05-31$760.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-08-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-11-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-02-28$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure(0.3)Income tax, Q2 FY2026, three months to 2026-05-31−$271.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure13.6Income tax, Q3 FY2026, three months to 2026-08-31$13.6m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure
Net income$m(42.0)Net income, Q4 FY2023, three months to 2023-11-30−$42.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(41.5)Net income, Q1 FY2024, three months to 2024-02-29−$41.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure(44.5)Net income, Q2 FY2024, three months to 2024-05-31−$44.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure(49.0)Net income, Q3 FY2024, three months to 2024-08-31−$49.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure(58.5)Net income, Q4 FY2024, three months to 2024-11-30−$58.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(56.4)Net income, Q1 FY2025, three months to 2025-02-28−$56.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure(43.5)Net income, Q2 FY2025, three months to 2025-05-31−$43.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure(86.4)Net income, Q3 FY2025, three months to 2025-08-31−$86.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure(78.2)Net income, Q4 FY2025, three months to 2025-11-30−$78.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(87.2)Net income, Q1 FY2026, three months to 2026-02-28−$87.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure(89.5)Net income, Q2 FY2026, three months to 2026-05-31−$89.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure550Net income, Q3 FY2026, three months to 2026-08-31$549.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure
Diluted EPS$ per sharenot reported(0.76)Diluted EPS, Q1 FY2024, three months to 2024-02-29−$0.76 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-04-08, accession 0001549595-25-000055.Report this figure(0.71)Diluted EPS, Q2 FY2024, three months to 2024-05-31−$0.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-07-09, accession 0001549595-25-000095.Report this figure(0.67)Diluted EPS, Q3 FY2024, three months to 2024-08-31−$0.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figurenot reported(0.67)Diluted EPS, Q1 FY2025, three months to 2025-02-28−$0.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure(0.52)Diluted EPS, Q2 FY2025, three months to 2025-05-31−$0.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure(1.03)Diluted EPS, Q3 FY2025, three months to 2025-08-31−$1.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figurenot reported(0.79)Diluted EPS, Q1 FY2026, three months to 2026-02-28−$0.79 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure(0.81)Diluted EPS, Q2 FY2026, three months to 2026-05-31−$0.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure4.73Diluted EPS, Q3 FY2026, three months to 2026-08-31$4.73 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure
Basic EPS$ per sharenot reported(0.76)Basic EPS, Q1 FY2024, three months to 2024-02-29−$0.76 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-04-08, accession 0001549595-25-000055.Report this figure(0.71)Basic EPS, Q2 FY2024, three months to 2024-05-31−$0.71 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-07-09, accession 0001549595-25-000095.Report this figure(0.67)Basic EPS, Q3 FY2024, three months to 2024-08-31−$0.67 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figurenot reported(0.67)Basic EPS, Q1 FY2025, three months to 2025-02-28−$0.67 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure(0.52)Basic EPS, Q2 FY2025, three months to 2025-05-31−$0.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure(1.03)Basic EPS, Q3 FY2025, three months to 2025-08-31−$1.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figurenot reported(0.79)Basic EPS, Q1 FY2026, three months to 2026-02-28−$0.79 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure(0.81)Basic EPS, Q2 FY2026, three months to 2026-05-31−$0.81 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure4.93Basic EPS, Q3 FY2026, three months to 2026-08-31$4.93 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure

Balance sheet

Cash and equivalents$720.2m, Q3 FY2026
Shareholders' equity$968.3m, Q3 FY2026
Nurix Therapeutics, Inc., balance sheet, quarterly
Line itemUnitFY20232023-11-30Q1 FY20242024-02-29Q2 FY20242024-05-31Q3 FY20242024-08-31FY20242024-11-30Q1 FY20252025-02-28Q2 FY20252025-05-31Q3 FY20252025-08-31FY20252025-11-30Q1 FY20262026-02-28Q2 FY20262026-05-31Q3 FY20262026-08-31
Cash and equivalents$m54.6Cash and equivalents, FY2023, at 2023-11-30$54.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-01-28, accession 0001549595-26-000016.Report this figure49.8Cash and equivalents, Q1 FY2024, at 2024-02-29$49.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-04-08, accession 0001549595-25-000055.Report this figure117Cash and equivalents, Q2 FY2024, at 2024-05-31$116.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-07-09, accession 0001549595-25-000095.Report this figure99.0Cash and equivalents, Q3 FY2024, at 2024-08-31$99.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure110Cash and equivalents, FY2024, at 2024-11-30$110.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-01-28, accession 0001549595-26-000016.Report this figure75.9Cash and equivalents, Q1 FY2025, at 2025-02-28$75.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure84.3Cash and equivalents, Q2 FY2025, at 2025-05-31$84.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure78.4Cash and equivalents, Q3 FY2025, at 2025-08-31$78.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure247Cash and equivalents, FY2025, at 2025-11-30$247.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure71.2Cash and equivalents, Q1 FY2026, at 2026-02-28$71.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure67.7Cash and equivalents, Q2 FY2026, at 2026-05-31$67.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure720Cash and equivalents, Q3 FY2026, at 2026-08-31$720.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure
Current assets$m296Current assets, FY2023, at 2023-11-30$295.5m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-01-28, accession 0001549595-25-000016.Report this figure251Current assets, Q1 FY2024, at 2024-02-29$251.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-04-10, accession 0001549595-24-000049.Report this figure450Current assets, Q2 FY2024, at 2024-05-31$450.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-07-11, accession 0001549595-24-000098.Report this figure456Current assets, Q3 FY2024, at 2024-08-31$456.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-10-11, accession 0001549595-24-000131.Report this figure619Current assets, FY2024, at 2024-11-30$619.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-01-28, accession 0001549595-26-000016.Report this figure564Current assets, Q1 FY2025, at 2025-02-28$563.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-04-08, accession 0001549595-25-000055.Report this figure515Current assets, Q2 FY2025, at 2025-05-31$515.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-07-09, accession 0001549595-25-000095.Report this figure441Current assets, Q3 FY2025, at 2025-08-31$440.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure607Current assets, FY2025, at 2025-11-30$606.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure554Current assets, Q1 FY2026, at 2026-02-28$554.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure456Current assets, Q2 FY2026, at 2026-05-31$456.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure1,104Current assets, Q3 FY2026, at 2026-08-31$1.10bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure
Total assets$m356Total assets, FY2023, at 2023-11-30$355.6m. XBRL concept us-gaap:Assets. 10-K filed 2025-01-28, accession 0001549595-25-000016.Report this figure313Total assets, Q1 FY2024, at 2024-02-29$312.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-04-10, accession 0001549595-24-000049.Report this figure511Total assets, Q2 FY2024, at 2024-05-31$511.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-07-11, accession 0001549595-24-000098.Report this figure514Total assets, Q3 FY2024, at 2024-08-31$513.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-10-11, accession 0001549595-24-000131.Report this figure669Total assets, FY2024, at 2024-11-30$669.3m. XBRL concept us-gaap:Assets. 10-K filed 2026-01-28, accession 0001549595-26-000016.Report this figure615Total assets, Q1 FY2025, at 2025-02-28$615.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-04-08, accession 0001549595-25-000055.Report this figure592Total assets, Q2 FY2025, at 2025-05-31$591.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-07-09, accession 0001549595-25-000095.Report this figure522Total assets, Q3 FY2025, at 2025-08-31$522.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure688Total assets, FY2025, at 2025-11-30$688.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure636Total assets, Q1 FY2026, at 2026-02-28$636.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure536Total assets, Q2 FY2026, at 2026-05-31$535.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure1,195Total assets, Q3 FY2026, at 2026-08-31$1.20bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure
Current liabilities$m87.0Current liabilities, FY2023, at 2023-11-30$87.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-01-28, accession 0001549595-25-000016.Report this figure87.6Current liabilities, Q1 FY2024, at 2024-02-29$87.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-04-10, accession 0001549595-24-000049.Report this figure80.8Current liabilities, Q2 FY2024, at 2024-05-31$80.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-07-11, accession 0001549595-24-000098.Report this figure86.3Current liabilities, Q3 FY2024, at 2024-08-31$86.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-10-11, accession 0001549595-24-000131.Report this figure95.9Current liabilities, FY2024, at 2024-11-30$95.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-01-28, accession 0001549595-26-000016.Report this figure90.0Current liabilities, Q1 FY2025, at 2025-02-28$90.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-04-08, accession 0001549595-25-000055.Report this figure75.6Current liabilities, Q2 FY2025, at 2025-05-31$75.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-07-09, accession 0001549595-25-000095.Report this figure82.4Current liabilities, Q3 FY2025, at 2025-08-31$82.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure86.5Current liabilities, FY2025, at 2025-11-30$86.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure92.2Current liabilities, Q1 FY2026, at 2026-02-28$92.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure72.0Current liabilities, Q2 FY2026, at 2026-05-31$72.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure131Current liabilities, Q3 FY2026, at 2026-08-31$130.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure
Total liabilities$m155Total liabilities, FY2023, at 2023-11-30$155.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-01-28, accession 0001549595-25-000016.Report this figure144Total liabilities, Q1 FY2024, at 2024-02-29$143.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-04-10, accession 0001549595-24-000049.Report this figure140Total liabilities, Q2 FY2024, at 2024-05-31$140.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-07-11, accession 0001549595-24-000098.Report this figure137Total liabilities, Q3 FY2024, at 2024-08-31$136.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-10-11, accession 0001549595-24-000131.Report this figure142Total liabilities, FY2024, at 2024-11-30$142.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-01-28, accession 0001549595-26-000016.Report this figure134Total liabilities, Q1 FY2025, at 2025-02-28$134.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-04-08, accession 0001549595-25-000055.Report this figure144Total liabilities, Q2 FY2025, at 2025-05-31$144.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-07-09, accession 0001549595-25-000095.Report this figure150Total liabilities, Q3 FY2025, at 2025-08-31$150.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure149Total liabilities, FY2025, at 2025-11-30$149.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure155Total liabilities, Q1 FY2026, at 2026-02-28$155.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure133Total liabilities, Q2 FY2026, at 2026-05-31$132.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure227Total liabilities, Q3 FY2026, at 2026-08-31$227.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure
Shareholders' equity$m200Shareholders' equity, FY2023, at 2023-11-30$200.5m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-01-28, accession 0001549595-26-000016.Report this figure169Shareholders' equity, Q1 FY2024, at 2024-02-29$168.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure371Shareholders' equity, Q2 FY2024, at 2024-05-31$370.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure377Shareholders' equity, Q3 FY2024, at 2024-08-31$376.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure527Shareholders' equity, FY2024, at 2024-11-30$527.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure481Shareholders' equity, Q1 FY2025, at 2025-02-28$480.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure448Shareholders' equity, Q2 FY2025, at 2025-05-31$447.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure372Shareholders' equity, Q3 FY2025, at 2025-08-31$372.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure539Shareholders' equity, FY2025, at 2025-11-30$538.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure481Shareholders' equity, Q1 FY2026, at 2026-02-28$480.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure403Shareholders' equity, Q2 FY2026, at 2026-05-31$402.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure968Shareholders' equity, Q3 FY2026, at 2026-08-31$968.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure

Cash flow

Operating cash flow$615.6m, Q3 FY2026
Capital expenditure$1.4m, Q3 FY2026
Nurix Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ4 FY20232023-11-30Q1 FY20242024-02-29Q2 FY20242024-05-31Q3 FY20242024-08-31Q4 FY20242024-11-30Q1 FY20252025-02-28Q2 FY20252025-05-31Q3 FY20252025-08-31Q4 FY20252025-11-30Q1 FY20262026-02-28Q2 FY20262026-05-31Q3 FY20262026-08-31
Operating cash flow$m26.7Operating cash flow, Q4 FY2023, three months to 2023-11-30$26.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(42.0)Operating cash flow, Q1 FY2024, three months to 2024-02-29−$42.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-04-08, accession 0001549595-25-000055.Report this figure(39.7)Operating cash flow, Q2 FY2024, three months to 2024-05-31−$39.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-07-09, accession 0001549595-25-000095. Derived: 6-month figure less the 3-month figure.Report this figure(42.2)Operating cash flow, Q3 FY2024, three months to 2024-08-31−$42.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-09, accession 0001549595-25-000113. Derived: 9-month figure less the 6-month figure.Report this figure(48.8)Operating cash flow, Q4 FY2024, three months to 2024-11-30−$48.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(61.1)Operating cash flow, Q1 FY2025, three months to 2025-02-28−$61.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure(63.2)Operating cash flow, Q2 FY2025, three months to 2025-05-31−$63.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-09, accession 0001549595-26-000040. Derived: 6-month figure less the 3-month figure.Report this figure(57.4)Operating cash flow, Q3 FY2025, three months to 2025-08-31−$57.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-13, accession 0001549595-26-000049. Derived: 9-month figure less the 6-month figure.Report this figure(67.8)Operating cash flow, Q4 FY2025, three months to 2025-11-30−$67.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(71.9)Operating cash flow, Q1 FY2026, three months to 2026-02-28−$71.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure(96.6)Operating cash flow, Q2 FY2026, three months to 2026-05-31−$96.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-09, accession 0001549595-26-000040. Derived: 6-month figure less the 3-month figure.Report this figure616Operating cash flow, Q3 FY2026, three months to 2026-08-31$615.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-13, accession 0001549595-26-000049. Derived: 9-month figure less the 6-month figure.Report this figure
Capital expenditure$m2.6Capital expenditure, Q4 FY2023, three months to 2023-11-30$2.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure2.9Capital expenditure, Q1 FY2024, three months to 2024-02-29$2.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-04-08, accession 0001549595-25-000055.Report this figure1.9Capital expenditure, Q2 FY2024, three months to 2024-05-31$1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-07-09, accession 0001549595-25-000095. Derived: 6-month figure less the 3-month figure.Report this figure2.3Capital expenditure, Q3 FY2024, three months to 2024-08-31$2.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-09, accession 0001549595-25-000113. Derived: 9-month figure less the 6-month figure.Report this figure2.1Capital expenditure, Q4 FY2024, three months to 2024-11-30$2.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure3.5Capital expenditure, Q1 FY2025, three months to 2025-02-28$3.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure2.7Capital expenditure, Q2 FY2025, three months to 2025-05-31$2.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-09, accession 0001549595-26-000040. Derived: 6-month figure less the 3-month figure.Report this figure2.7Capital expenditure, Q3 FY2025, three months to 2025-08-31$2.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-13, accession 0001549595-26-000049. Derived: 9-month figure less the 6-month figure.Report this figure5.1Capital expenditure, Q4 FY2025, three months to 2025-11-30$5.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-01-28, accession 0001549595-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure1.0Capital expenditure, Q1 FY2026, three months to 2026-02-28$1.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure1.9Capital expenditure, Q2 FY2026, three months to 2026-05-31$1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-09, accession 0001549595-26-000040. Derived: 6-month figure less the 3-month figure.Report this figure1.4Capital expenditure, Q3 FY2026, three months to 2026-08-31$1.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-13, accession 0001549595-26-000049. Derived: 9-month figure less the 6-month figure.Report this figure

Shares

Diluted shares (weighted)116.15m, Q3 FY2026
Nurix Therapeutics, Inc., shares, quarterly
Line itemUnitQ1 FY20232023-02-28Q2 FY20232023-05-31Q3 FY20232023-08-31Q1 FY20242024-02-29Q2 FY20242024-05-31Q3 FY20242024-08-31Q1 FY20252025-02-28Q2 FY20252025-05-31Q3 FY20252025-08-31Q1 FY20262026-02-28Q2 FY20262026-05-31Q3 FY20262026-08-31
Diluted shares (weighted)m shares54.0Diluted shares (weighted), Q1 FY2023, three months to 2023-02-2854,028,238 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-04-10, accession 0001549595-24-000049.Report this figure54.3Diluted shares (weighted), Q2 FY2023, three months to 2023-05-3154,259,045 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-07-11, accession 0001549595-24-000098.Report this figure54.4Diluted shares (weighted), Q3 FY2023, three months to 2023-08-3154,390,859 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-10-11, accession 0001549595-24-000131.Report this figure54.9Diluted shares (weighted), Q1 FY2024, three months to 2024-02-2954,903,407 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-04-08, accession 0001549595-25-000055.Report this figure62.4Diluted shares (weighted), Q2 FY2024, three months to 2024-05-3162,377,551 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-07-09, accession 0001549595-25-000095.Report this figure72.8Diluted shares (weighted), Q3 FY2024, three months to 2024-08-3172,779,381 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-10-09, accession 0001549595-25-000113.Report this figure83.6Diluted shares (weighted), Q1 FY2025, three months to 2025-02-2883,560,795 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure83.9Diluted shares (weighted), Q2 FY2025, three months to 2025-05-3183,882,477 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure84.2Diluted shares (weighted), Q3 FY2025, three months to 2025-08-3184,159,336 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure110Diluted shares (weighted), Q1 FY2026, three months to 2026-02-28110,071,668 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-04-08, accession 0001549595-26-000025.Report this figure111Diluted shares (weighted), Q2 FY2026, three months to 2026-05-31111,084,423 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-07-09, accession 0001549595-26-000040.Report this figure116Diluted shares (weighted), Q3 FY2026, three months to 2026-08-31116,152,771 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure

Shares outstanding: 109.25mShares outstanding, period not labelled, at 2026-09-30109,249,814 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-10-13, accession 0001549595-26-000049.Report this figure at Sep 30, 2026, from the cover of the 10-Q filed Oct 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.